What is the recommended dose of Xarelto (rivaroxaban) for atrial fibrillation (AFib)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
DS

Dainyal Siddiqui, MD

Internal Medicine

MJ

Manuel Jimenez, MD

Cardiology

FP

Franz Pierre-Louis, MD

Infectious Disease

Article Review Status
Submitted
Under Review
Approved

Last updated: April 1, 2025 • View editorial policy

From the Guidelines

The standard dose of Xarelto (rivaroxaban) for atrial fibrillation is 20 mg once daily taken with food, but for patients with reduced kidney function (creatinine clearance between 15-50 mL/min), the dose should be reduced to 15 mg once daily with food. This recommendation is based on the most recent guidelines from the European Society of Cardiology, as outlined in the 2024 ESC guidelines for the management of atrial fibrillation 1. The dose reduction for patients with renal impairment is crucial to minimize the risk of bleeding and ensure the optimal prevention of thromboembolism related to atrial fibrillation.

Key Considerations

  • The dose of Xarelto should be adjusted based on the patient's kidney function, with a reduced dose of 15 mg once daily recommended for patients with creatinine clearance between 15-49 mL/min 1.
  • Patients should take Xarelto at the same time each day to maintain consistent blood levels, and it is essential to take the medication with food.
  • Xarelto works by inhibiting Factor Xa, which prevents blood clot formation that could lead to stroke in patients with atrial fibrillation.
  • Patients should not stop taking Xarelto without consulting their doctor, as this could increase stroke risk.
  • Common side effects of Xarelto include bleeding, bruising, and dizziness, and any unusual bleeding should be reported to a healthcare provider immediately.

Monitoring and Follow-up

  • Unlike warfarin, Xarelto does not require regular blood tests to monitor its effect, but kidney function should be assessed periodically to ensure the appropriate dose is maintained 2.
  • The European Medicines Association Summary of Product Characteristics for each direct oral anticoagulant (DOAC) provides guidance on dose adjustments and patient-specific considerations 1.

From the FDA Drug Label

Adults Advise patients with atrial fibrillation to take XARELTO once daily with the evening meal.

The dose of XARELTO for atrial fibrillation is once daily with the evening meal 3.

  • The specific dose is not mentioned in this section, but it can be found in the Dosage and Administration section.
  • However, the label does mention that for initial treatment of DVT and/or PE, the dose is 15 mg or 20 mg tablets with food at approximately the same time every day.
  • And for patients who are at a continued risk of recurrent DVT and/or PE after at least 6 months of initial treatment, the dose is 10 mg once daily with or without food.
  • But for afib, the dose should be taken once daily with the evening meal, the exact dose is not specified in this part of the label.

From the Research

Xarelto Dose for Atrial Fibrillation

The dose of Xarelto (rivaroxaban) for patients with atrial fibrillation (AF) can vary depending on renal function.

  • For patients with creatinine clearance (CrCl) 15-29 mL/min, a dose of 10 mg once daily is proposed 4
  • For patients with CrCl 30-69 mL/min, a dose of 15 mg once daily is recommended 4, 5
  • For patients with CrCl 70-159 mL/min, a dose of 10 mg twice daily is proposed, although this is not a standard dosing regimen 4
  • For patients with CrCl 160-250 mL/min, a dose of 15 mg twice daily is proposed, although this is not a standard dosing regimen 4

Renal Impairment Considerations

Patients with renal impairment may require dose adjustments.

  • A study found that rivaroxaban was often administered underdosed in clinical practice, with potentially inappropriate dose reduction significantly associated with estimated glomerular filtration rate (eGFR) 5
  • Another study suggested that apixaban may have a lower risk of major bleeding and comparable risk of stroke when compared with warfarin in AF patients with end-stage renal disease (ESRD) 6

Study Findings

A prospective interventional study (X-TRA) and a retrospective observational registry (CLOT-AF) were planned to explore the efficacy of rivaroxaban in the treatment of left atrial/left atrial appendage thrombi in patients with nonvalvular AF or atrial flutter 7

  • The primary objective of the X-TRA study was to explore the efficacy of rivaroxaban in the treatment of LA/LAA thrombi in patients with nonvalvular AF or atrial flutter
  • The CLOT-AF registry aimed to provide retrospective thrombus-related patient outcome data after standard-of-care anticoagulant treatment in patients with nonvalvular AF or atrial flutter

References

Related Questions

What is the dose of Xarelto (rivaroxaban) for atrial fibrillation?
What is the recommended dose of Xarelto (Rivaroxaban) for new onset atrial fibrillation?
What is the recommended dose of rivaroxaban (Xarelto) for elderly adult patients with atrial fibrillation and impaired renal function?
What are the loading doses of Rivaroxaban (Xarelto)?
Can Atrial Fibrillation (Afib) cause arterial thrombosis?
What are the treatment options for joint pain in patients with positive Anti-Ro (SS-A) Antibodies (Sjögren's Syndrome Antigen A)?
What are the causes of mildly elevated troponin levels, specifically 18, in a 60-year-old asymptomatic woman with a history of normal cardiac catheterization (cardiac cath) two years ago?
Does hydroxyzine affect melatonin production?
Is a fasting blood glucose level in the 90s, in a person in their early 20s with a strong family history of Type 2 Diabetes (T2D), indicative of prediabetes?
What causes secondary imbalance of the inner ear equilibrium system?
How often should Pap (Papanicolau) smear and HPV (Human Papillomavirus) testing be performed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Ask a new Question. Chat with the Guidelines